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ABSTRACT
The genetic alphabet consists of the four letters: C, A, G, and T in DNA and C,A,G, and U in RNA. Triplets of
these four letters jointly encode 20 different amino acids out of which proteins of all organisms are built.
This system is universal and is found in all kingdoms of life. However, bases in DNA and RNA can be
chemically modified. In DNA, around 10 different modifications are known, and those have been studied
intensively over the past 20 years. Scientific studies on DNA modifications and proteins that recognize
them gave rise to the large field of epigenetic and epigenomic research. The outcome of this intense
research field is the discovery that development, ageing, and stem-cell dependent regeneration but also
several diseases including cancer are largely controlled by the epigenetic state of cells. Consequently, this
research has already led to the first FDA approved drugs that exploit the gained knowledge to combat
disease. In recent years, the ~150 modifications found in RNA have come to the focus of intense research.
Here we provide a perspective on necessary and expected developments in the fast expanding area of
RNA modifications, termed epitranscriptomics.
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Epitranscriptomics, an expanding research area with great
potential for biomedicine, biotechnology and crop
production.
In contrast to DNA modifications, nucleotide modifications
in RNA are far more diverse and abundant, with more than
140 modifications known to date. Modifications in RNA can
change the coding of messenger RNAs (mRNAs) and therefore
diversify genetic information. Most RNA modifications cannot
be identified by traditional sequencing methods. Thus, despite
huge investments in RNA Seq, we are still missing an important
layer of cellular diversity. Modifications can also affect the
processing/splicing, localization, stability, turnover, or transla-
tion of mRNAs. Importantly, RNA modifications can be
applied transiently, allowing a fast response to changing cellular
or environmental conditions. Lastly, similar to the findings of
epigenetics research in DNA, groups of proteins have been
identified that specifically recognize and bind modified nucleo-
tides thereby affecting the fate of RNA.
Not all RNA modifications can be synthesized by the organ-
isms in which they are found, but can be delivered as a nutrient
by the microbiome, therefore regulating host-microbe interac-
tions. Revealing the mechanisms of specific uptake of these
chemical “precursors” and their installation as RNA modifica-
tions will not only provide information on the metabolism of
these substances and cellular pathways, but likely reveal new
diseases linked to the machineries involved. RNA modification
can also be involved in cell-to-cell horizontal transfer of infor-
mation mediated by extracellular vesicles.
Most importantly, changes in RNA modifications have been
recognized as being the cause of several diseases ranging from
immune disorders, over neuromuscular defects, to cancer.
Already this knowledge is used and methods that aim at redi-
recting specific modifications to clinically relevant sites are
being tested.
Thus, today, 30 years after the advent of molecular research
in epigenetics, we anticipate a similar, if not bigger explosion in
Epitranscriptome research with even a larger impact on biomed-
ical, pharmaceutical, livestock, and agricultural developments.
International development: A wakeup call for Europe
Indeed, several countries have already recognized the potential
impact of this new research area. For instance, the NIH in the
USA has opened two specialized calls to explore the impact of the
epitranscriptome on cancer (https://grants.nih.gov/grants/guide/
pa-files/PA-16-177.html) and on brain development (https://
grants.nih.gov/grants/guide/pa-files/PAR-17-152.html).
Similarly, Germany has one running and one starting joint
research project on the Chemical Biology of Epigenetic Modifi-
cations and Chemical Biology of native Nucleic Acid Modifica-
tions, to name a few. The large interest in epitranscriptome
research is also reflected by the number of reviews on this topic
in the major scientific journals, now almost appearing on a
monthly basis.
Thus the international development makes it clear that Epi-
transcriptome research is an emerging field with high potential.
With some international and many national institutions rush-
ing ahead, it is of utmost importance for European science
development to establish coordinated funding at the European
level.
A COST Action consortium on the Epitranscriptome
termed “EPITRAN” (European Epitrancriptomics Network)
has already been launched in 2017 with the aim to coordinate a
synergistic network of Epitranscriptome research at the Euro-
pean level and to generate the awareness required to acquire
European funding on this topic. It currently counts 26 member
states and 60 management members. Already in its first year,
three networking events are being organized.
The impact of a coordinated European
Epitranscriptome network
Coordinated European Epitranscriptome research will affect
health, wealth, nutrition and the environment within
Europe. The dramatic increase in the number of diseases
shown to be linked to changes in RNA modifications indi-
cates major impact in virtually all fields of life and health
science. Developing novel methods for the detection of
modification patterns or tools for the manipulation of rele-
vant modifications will provide the basis for the develop-
ment of new diagnostics and therapeutics. Here we list the
most prominent areas already known to be impacted by
RNA modifications where an obvious profit from increased
efforts in R&D is foreseeable:
Biomarkers, diagnostics & personalized medicine
 The recognition that cellular differentiation, cancer but
also specific diseases of the immune or the neuromuscu-
lar system are associated with or even caused by altered
RNA modifications indicates that improved tools for the
detection of epitranscriptomic marks as biomarkers will
be of great diagnostic value.
 Altered mitochondrial tRNA modifications are a frequent
underlying cause of neuromuscular disorders. Future
therapies will rely on the targeted restoration of missing
or misplaced marks.
 Changes in cytoplasmic tRNA modifications are disease
related and a frequent cause of neuropathies such as ALS
or epilepsy. These can be used for diagnostics and as spe-
cific targets for novel therapies.
Drug development
 Understanding the machineries and factors that intro-
duce, remove, or read RNA modifications will allow their
inhibition by the development of novel drugs with phar-
maceutical value (e.g. novel antibiotics, antifungal, anti
antiprotozoal therapies).
 Changes in the modification patterns of transformed cells
can be exploited to develop specific and personalized
drugs, e.g. drags that target the “cancer ribosome”.
 Elucidating the type, distribution, and occurrence of epi-
transcriptomic modifications in pathogens and their
hosts will allow the development of novel vaccines or
antibiotics.
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 RNA modifications will be important to bypass resistance
against existing antibiotics but also to develop novel
antibiotics.
 Site directed removal or addition of modifications can be
used to affect the fate and coding potential of therapeuti-
cally important RNAs.
 Similarly, undesired immune responses against nucleic
acids can be shielded by applying the appropriate modifi-
cations to facilitate nucleic acids based therapies.
Agriculture
 A better understanding of the proteins that read the epi-
transcriptomic marks will provide opportunities for
breeding of more resilient crops. For example, the tran-
scripts from a particular set of genes may always be
“tagged” by an epitranscriptomic mark, but whether this
causes preferential translation, storage or degradation
could be dependent on modifications to the readers
which could take place within seconds of an environmen-
tal stress signal.
 From an environmental perspective it is clear that altered
modifications can be found associated with stress responses
and altered environmental conditions. In times where cli-
mates are becoming more extreme and crops need to be
more resistant, RNA modifications will become an impor-
tant factor for the understanding but also manipulation of
stress response, both in plants and inmetazoan systems.
Nutrition
 Given that precursors of modifications are provided
through nutrients, translational efficiency and fidelity can
be affected by directed alteration of nutrients.
Biotechnology
 Improved sequencing technologies will allow Biotech
companies to explore new markets for the detection of
epitranscriptomic marks.
 Orthogonal translation for the specific labeling or genera-
tion of novel proteins may be further developed by expand-
ing the ribosomal and tRNAmodification repertoire.
 Biotechnology will profit from the development of
improved protein translation machineries by manipulat-
ing both ribosomes and mRNAs.
RNA modifications will be used to develop improved biotech-
niques for synthesis and analysis of RNA molecules.
European excellence
 Concentrating excellent Epitranscriptome research in
Europe will not only create a world-leading scientific
research community on this topic, but also lead to the
establishment of new startups and attract industrial part-
ners, e.g. pharmaceutical companies, thereby creating a
large number of jobs in this industry.
Outlook
It is clear that a new era of research on RNA modifications has
already begun. Europe needs to concentrate forces in a syner-
gistic manner by coordinating efforts of the leading groups in
this field, so as to catch up with other worldwide research ini-
tiatives. It is already foreseeable that this Epitranscriptomic era
will change our understanding of many aspects of biology, bio-
medicine, agriculture, and ecology. Importantly, new standard-
ized tools for epitranscriptome research but also standardized
bioinformatics solutions have to be developed with biotechnol-
ogy companies and software developers to allow comparable
and compatible research outcomes and dissemination of high-
throughput data. Similarly, links with pharmaceutical and agri-
cultural industries need to be strengthened to allow translation
of the gained knowledge into biomarker development, diagnos-
tics, drug development, and novel crop production.
Joint research projects will enable Europe to stay ahead of
these novel developments, tackle upcoming research challenges,
and provide appropriate trainings for a new generation of sci-
entists, pharmaceutical and agricultural researchers. Coordi-
nated research efforts will therefore allow Europe to take
maximum advantage of novel developments and therefore
position itself as a leader in the development of novel bio-
markers, therapies, and nutrients.
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